Business Wire

Cepton Unveils Vista®-X90, Sets New Standard for High Performance, Automotive-Grade Lidar

22.9.2020 15:00:00 EEST | Business Wire | Press release

Share

Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced details of its groundbreaking automotive-grade lidar sensor – the Vista®-X90, priced at less than $1000 for high volume automotive applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005088/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, the compact, non-rotational Vista-X90 allows seamless vehicle integration. © 2020 Cepton Technologies.

The Vista-X90 is the newest addition to Cepton’s Vista-X automotive grade sensor family. It sets a new benchmark for high performance at low power in a compact form factor, and is ideally suited for advanced driver assistance systems (ADAS) and autonomous vehicles (AVs). Weighing less than 900 g, the Vista-X90 achieves up to 200 m range at 10% reflectivity with an outstanding angular resolution of 0.13° and state-of-the-art power consumption of <12W. The sensor supports frame rates of up to 40 Hz.

Optimized for ease of vehicle integration, the Vista-X90 has a licensable design architecture powered by Cepton’s patented Micro Motion Technology (MMT®) – a frictionless, mirrorless, rotation-free lidar architecture capable of high resolution and long range 3D imaging, while maximizing the sensor robustness and reliability to meet the stringent requirements of automotive applications.

Powered by Cepton’s next generation ASIC technology, the Vista-X90 is an ISO26262 ASIL-B sensor that supports AUTOSAR and over-the-air (OTA) functionality, with advanced capabilities for factory, extrinsic and dynamic calibration. With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, Vista-X90 is compact and embeddable. Its 90° x 25° field of view, combined with its directional, non-rotational design allows seamless vehicle integration - such as in the fascia, behind the windshield or on the roof.

Built with easily available and inexpensive components using a highly manufacturable, modular and scalable architecture, the Vista-X90 is ideally suited for high volume production to bring truly cost-effective lidar solutions to ADAS and AV markets. Cepton has licensed its technology to the world’s largest automotive headlamp Tier 1, Koito, who has non-exclusive rights to manufacture and sell Cepton’s lidar technology for an automotive application, using key modules supplied by Cepton.

“We are excited to disrupt the industry with the Vista-X90, which is the most cost-effective, high-performance lidar in the world for automotive applications,” said Dr. Jun Pei, Cepton’s CEO. “Automotive lidars have historically had either low performance at acceptable cost or claimed high performance while being too expensive for many OEM programs. The Vista-X90 fundamentally changes the game by bridging that divide and delivering the optimal mix of performance, power, reliability and cost. This is an integral part of our plan to make lidar available as an essential safety device in every consumer vehicle in the world.”

The Vista-X90 is targeted for production in 2022 and beyond, and samples can be made available upon request.

To learn more about the Vista-X90 and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming Automotive Lidar 2020 conference next week, between September 22 – 24, 2020. Please visit our virtual booth page and sign up to hear Cepton’s Senior Director of Business Development, Mitch Hourtienne, discuss the Vista lidars in his talk “Importance of Tier 1 Collaboration for an Automotive ADAS Production Program” on September 23 at 11:15 am EST.

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as autonomous driving, ADAS, intelligent transportation systems (ITS), smart spaces and industrial robotics. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, UK, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Faithy Li, Cepton Technologies, media@cepton.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye